Last 7 days
10.2%
Last 30 days
11.8%
Last 90 days
17.1%
Trailing 12 Months
117.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 409.0B | 96.3B | -3.62% | -9.57% | 32.14 | 4.25 | 1.46% | -35.83% |
LLY | 398.5B | 27.7B | 2.58% | 47.15% | 70.08 | 14.39 | -5.56% | -7.22% |
MRK | 272.8B | 57.9B | -4.82% | 28.79% | 17.88 | 4.63 | 7.21% | -8.11% |
PFE | 230.9B | 93.0B | -0.23% | -25.99% | 7.36 | 2.3 | 0.56% | 16.36% |
BMY | 150.1B | 45.8B | -1.47% | -11.26% | 23.72 | 3.25 | -2.37% | 16.96% |
MID-CAP | ||||||||
PRGO | 5.0B | 4.6B | -12.00% | -16.92% | -35.25 | 1.11 | 8.46% | -29.07% |
RETA | 3.5B | 1.5M | -8.84% | 225.36% | -11.32 | 1.6K | -86.94% | -16.59% |
SMALL-CAP | ||||||||
SUPN | 1.8B | 668.5M | -9.91% | 19.28% | 34.95 | 2.72 | 11.17% | -29.04% |
TLRY | 1.6B | 596.3M | -7.75% | -62.41% | -0.89 | 2.66 | -3.41% | -3791.67% |
INVA | 866.9M | 271.5M | 14.22% | -13.24% | 3.94 | 3.19 | -31.50% | -40.28% |
CRON | 666.4M | 112.3M | -6.91% | -41.08% | -4.29 | 5.94 | 7.69% | 41.96% |
ACRS | 590.7M | 30.8M | -2.33% | -39.30% | -6.14 | 19.16 | 378.90% | -19.01% |
OCUL | 536.4M | 51.7M | 11.79% | 117.61% | -6.04 | 10.38 | 4.69% | -299.77% |
CGC | 401.1M | 478.9M | -31.81% | -82.48% | -0.13 | 0.84 | -31.50% | -634.70% |
ENDP | 94.1M | 2.2B | -43.99% | -88.43% | -0.03 | 0.04 | -25.47% | -292.77% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 0.4% | 51,680 | 51,494 | 49,726 | 49,914 | 49,366 |
S&GA Expenses | 4.4% | 41,693 | 39,922 | 38,525 | 37,915 | 36,166 |
R&D Expenses | 3.1% | 55,109 | 53,462 | 52,497 | 51,497 | 52,256 |
Interest Expenses | 1.2% | 7,108 | 7,022 | 6,856 | 6,717 | 6,676 |
Net Income | -25.0% | -88,814 | -71,038 | -59,346 | -32,501 | -22,216 |
Net Income Margin | -15.6% | -1.38* | -1.19* | -0.65* | -0.45* | - |
Free Cahsflow | -5.5% | -63,318 | -59,994 | -59,289 | -68,103 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -13.9% | 129 | 149 | 159 | 173 | 188 |
Current Assets | -17.3% | 107 | 130 | 146 | 160 | 175 |
Cash Equivalents | -21.0% | 81.00 | 102 | 121 | 135 | 145 |
Inventory | 14.8% | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Net PPE | 22.0% | 12.00 | 10.00 | 7.00 | 7.00 | 7.00 |
Liabilities | 4.3% | 119 | 114 | 112 | 107 | 108 |
Current Liabilities | -5.4% | 30.00 | 31.00 | 29.00 | 26.00 | 24.00 |
Shareholder's Equity | -72.6% | 10.00 | 35.00 | 46.00 | 66.00 | 80.00 |
Retained Earnings | -4.9% | -647 | -616 | -601 | -577 | -558 |
Additional Paid-In Capital | 0.7% | 657 | 652 | 648 | 643 | 638 |
Shares Outstanding | 0.4% | 78.00 | 77.00 | 77.00 | 77.00 | 77.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -2.3% | -60,976 | -59,603 | -57,798 | -57,611 | -66,791 |
Share Based Compensation | 2.1% | 17,327 | 16,964 | 16,571 | 16,089 | 16,100 |
Cashflow From Investing | -83.5% | -6,818 | -3,715 | -2,196 | -1,678 | -1,312 |
Cashflow From Financing | -3.5% | 1,403 | 1,454 | 1,663 | 1,968 | 4,142 |
98.8%
97.3%
72.3%
Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.
-7.4%
0.3%
-0.7%
FIve years rolling returns for Ocular Therapeutix.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -11.52 | 30,172 | 75,930 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 16.51 | 101,663 | 186,663 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 38.69 | 207,000 | 337,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -41.11 | 16,000 | 166,000 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | 615 | 1,318 | -% |
2023-05-16 | ATLAS CAPITAL ADVISORS LLC | unchanged | - | 12,300 | 26,350 | -% |
2023-05-16 | JANE STREET GROUP, LLC | added | 323 | 539,212 | 616,832 | -% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 84.87 | 917,179 | 1,288,930 | -% |
2023-05-15 | Cubist Systematic Strategies, LLC | new | - | 226,552 | 226,552 | -% |
2023-05-15 | Quantamental Technologies LLC | new | - | 70,254 | 70,254 | 0.04% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | opaleye management inc. | 7.89% | 6,075,000 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 5.16% | 3,976,853 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.4% | 4,952,737 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 6.7% | 5,122,835 | SC 13G/A | |
Feb 01, 2022 | opaleye management inc. | 7.80% | 5,974,800 | SC 13G/A | |
Feb 12, 2021 | opaleye management inc. | 8.65% | 9 | SC 13G/A | |
Feb 02, 2021 | blackrock inc. | 7.3% | 5,512,264 | SC 13G | |
Jun 09, 2020 | blackrock inc. | 4.8% | 3,006,167 | SC 13G/A | |
May 21, 2020 | summer road llc | 17.0% | 11,387,656 | SC 13D/A | |
Mar 25, 2020 | summer road llc | 18.9% | 11,024,020 | SC 13D/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 08, 2023 | 8-K | Current Report | |
May 08, 2023 | 10-Q | Quarterly Report | |
May 01, 2023 | DEFA14A | DEFA14A | |
May 01, 2023 | DEF 14A | DEF 14A | |
May 01, 2023 | ARS | ARS | |
Apr 06, 2023 | 8-K | Current Report | |
Mar 06, 2023 | S-8 | Employee Benefits Plan | |
Mar 06, 2023 | 8-K | Current Report | |
Mar 06, 2023 | 10-K | Annual Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-06 | Mattessich Antony C. | sold | -83,396 | 4.24 | -19,669 | president and ceo |
2023-02-06 | White Christopher G | sold | -24,715 | 4.24 | -5,829 | chief business officer |
2023-02-06 | Ozden Rabia Gurses | sold | -27,203 | 4.24 | -6,416 | chief medical officer |
2023-02-06 | Notman Donald | sold | -27,458 | 4.24 | -6,476 | chief financial officer |
2023-02-06 | Strassburger Philip C. | sold | -26,207 | 4.24 | -6,181 | general counsel |
2023-01-30 | Notman Donald | acquired | - | - | 55,556 | chief financial officer |
2023-01-30 | Ozden Rabia Gurses | acquired | - | - | 55,556 | chief medical officer |
2023-01-30 | Strassburger Philip C. | acquired | - | - | 55,556 | general counsel |
2023-01-30 | Mattessich Antony C. | acquired | - | - | 176,300 | president and ceo |
2023-01-30 | White Christopher G | acquired | - | - | 44,444 | chief business officer |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue: | ||
Total revenue, net | $ 13,374 | $ 13,187 |
Costs and operating expenses: | ||
Cost, Product and Service [Extensible List] | Product | Product |
Cost of product revenue | $ 1,214 | $ 1,300 |
Research and development | 14,747 | 13,100 |
Selling and marketing | 10,835 | 9,063 |
General and administrative | 9,127 | 7,557 |
Total costs and operating expenses | 35,923 | 31,020 |
Loss from operations | (22,549) | (17,833) |
Other income (expense): | ||
Interest income | 563 | 18 |
Interest expense | (1,768) | (1,683) |
Change in fair value of derivative liability | (6,563) | 6,958 |
Other expense, net | (1) | (2) |
Total other (expense) income, net | (7,769) | 5,291 |
Net loss | $ (30,318) | $ (12,542) |
Net loss per share, basic | $ (0.39) | $ (0.16) |
Weighted average common shares outstanding, basic | 77,386,287 | 76,745,663 |
Net loss per share, diluted | $ (0.39) | $ (0.22) |
Weighted average common shares outstanding, diluted | 77,386,287 | 82,514,895 |
Product | ||
Revenue: | ||
Total revenue, net | $ 13,214 | $ 12,498 |
Collaboration revenue | ||
Revenue: | ||
Total revenue, net | $ 160 | $ 689 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 79,026 | $ 102,300 |
Accounts receivable, net | 21,124 | 21,325 |
Inventory | 2,266 | 1,974 |
Prepaid expenses and other current assets | 4,746 | 4,028 |
Total current assets | 107,162 | 129,627 |
Property and equipment, net | 12,022 | 9,856 |
Restricted cash | 1,764 | 1,764 |
Operating lease assets | 7,625 | 8,042 |
Total assets | 128,573 | 149,289 |
Current liabilities: | ||
Accounts payable | 5,441 | 5,123 |
Accrued expenses and other current liabilities | 21,993 | 24,097 |
Deferred revenue | 463 | 576 |
Operating lease liabilities | 1,818 | 1,599 |
Total current liabilities | 29,715 | 31,395 |
Other liabilities: | ||
Operating lease liabilities, net of current portion | 8,114 | 8,678 |
Derivative liability | 12,914 | 6,351 |
Deferred revenue, net of current portion | 13,340 | 13,387 |
Notes payable, net of discount | 25,321 | 25,257 |
Other non-current liabilities | 100 | 93 |
2026 convertible notes, net | 29,358 | 28,749 |
Total liabilities | 118,862 | 113,910 |
Commitments and contingencies (Note 14) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022, respectively | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,516,638 and 77,201,819 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 8 | 8 |
Additional paid-in capital | 656,863 | 652,213 |
Accumulated deficit | (647,160) | (616,842) |
Total stockholders' equity | 9,711 | 35,379 |
Total liabilities and stockholders' equity | $ 128,573 | $ 149,289 |